James E. Bradner

11.1k total citations · 2 hit papers
63 papers, 4.5k citations indexed

About

James E. Bradner is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, James E. Bradner has authored 63 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Molecular Biology, 26 papers in Hematology and 18 papers in Oncology. Recurrent topics in James E. Bradner's work include Protein Degradation and Inhibitors (32 papers), Histone Deacetylase Inhibitors Research (23 papers) and Multiple Myeloma Research and Treatments (17 papers). James E. Bradner is often cited by papers focused on Protein Degradation and Inhibitors (32 papers), Histone Deacetylase Inhibitors Research (23 papers) and Multiple Myeloma Research and Treatments (17 papers). James E. Bradner collaborates with scholars based in United States, Germany and United Kingdom. James E. Bradner's co-authors include Kapil N. Bhalla, Warren Fiskus, Jun Qi, Peter Atadja, Fei Guo, Edward Seto, Kathy Rocha, Michael Pranpat, Sandhya Boyapalle and Purva Bali and has published in prestigious journals such as Cell, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

James E. Bradner

61 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

2005 644 citations James E. Bradner et al. profile →
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

2012 488 citations Andrew L. Kung, Ralph Mazitschek et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James E. Bradner United States	28	3.6k	1.3k	792	400	368	63	4.5k
John F. Lyons United States	32	2.7k 0.7×	1.3k 1.0×	577 0.7×	347 0.9×	276 0.8×	81	4.3k
Mariateresa Fulciniti United States	34	2.6k 0.7×	1.5k 1.2×	1.4k 1.8×	638 1.6×	199 0.5×	155	4.1k
Gaël Roué Spain	33	1.7k 0.5×	864 0.7×	385 0.5×	552 1.4×	272 0.7×	101	3.0k
Marion Dorsch United States	32	2.2k 0.6×	1.2k 1.0×	329 0.4×	889 2.2×	170 0.5×	55	3.7k
Jian Hou China	30	1.7k 0.5×	1.1k 0.9×	1.1k 1.4×	634 1.6×	173 0.5×	154	2.9k
Hans‐Günter Zerwes Switzerland	27	1.4k 0.4×	1.1k 0.8×	384 0.5×	1.0k 2.6×	227 0.6×	58	3.8k
John D. Hooper Australia	35	1.9k 0.5×	1.1k 0.8×	820 1.0×	406 1.0×	156 0.4×	120	4.1k
Keith Dredge United States	30	2.2k 0.6×	983 0.8×	1.3k 1.7×	613 1.5×	139 0.4×	55	3.7k
Todd VanArsdale United States	27	1.7k 0.5×	1.4k 1.1×	280 0.4×	1.0k 2.6×	268 0.7×	48	3.7k
Rebecca J. Chan United States	32	2.2k 0.6×	531 0.4×	580 0.7×	917 2.3×	102 0.3×	90	3.3k

Countries citing papers authored by James E. Bradner

Since Specialization

Citations

This map shows the geographic impact of James E. Bradner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Bradner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Bradner more than expected).

Fields of papers citing papers by James E. Bradner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James E. Bradner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Bradner. The network helps show where James E. Bradner may publish in the future.

Co-authorship network of co-authors of James E. Bradner

This figure shows the co-authorship network connecting the top 25 collaborators of James E. Bradner. A scholar is included among the top collaborators of James E. Bradner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James E. Bradner. James E. Bradner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chory, Emma J., Meng Wang, Michele Ceribelli, et al.. (2023). High-throughput approaches to uncover synergistic drug combinations in leukemia. SLAS DISCOVERY. 28(4). 193–201. 4 indexed citations

Sewastianik, Tomasz, Hyuk‐Soo Seo, David Remillard, et al.. (2022). A novel β-catenin/BCL9 complex inhibitor blocks oncogenic Wnt signaling and disrupts cholesterol homeostasis in colorectal cancer. Science Advances. 8(17). eabm3108–eabm3108. 26 indexed citations

Carbonneau, Seth, Sujata Sharma, Liaomin Peng, et al.. (2020). An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity. Cell chemical biology. 28(6). 802–812.e6. 31 indexed citations

Wakimoto, Hiroko, Zhe Jiao, Joshua Gorham, et al.. (2020). BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy. JCI Insight. 5(15). 22 indexed citations

Ott, Christopher J., Alexander Federation, Siddha Kasar, et al.. (2018). Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. Cancer Cell. 34(6). 982–995.e7. 75 indexed citations

Cheng, Jingwei, Donglim Esther Park, Christian Berrios, et al.. (2017). Merkel cell polyomavirus recruits MYCL to the EP400 complex to promote oncogenesis. PLoS Pathogens. 13(10). e1006668–e1006668. 92 indexed citations

Chakraborty, Abhishek A., Eijiro Nakamura, Jun Qi, et al.. (2017). HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase. Science Translational Medicine. 9(398). 36 indexed citations

Bhattacharyya, Sanchari, Kith Pradhan, Nathaniel R. Campbell, et al.. (2017). Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways. Genome Research. 27(11). 1830–1842. 48 indexed citations

Xie, Huafeng, Cong Peng, Jialiang Huang, et al.. (2016). Chronic Myelogenous Leukemia– Initiating Cells Require Polycomb Group Protein EZH2. Cancer Discovery. 6(11). 1237–1247. 73 indexed citations

10.

Saint‐André, Violaine, Alexander Federation, Charles Y. Lin, et al.. (2016). Models of human core transcriptional regulatory circuitries. Genome Research. 26(3). 385–396. 169 indexed citations

11.

Zhu, Hengrui, Fee Bengsch, Nikolaos Svoronos, et al.. (2016). BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. Cell Reports. 16(11). 2829–2837. 343 indexed citations

12.

Schölz, Christian, Brian T. Weinert, Sebastian Wagner, et al.. (2015). Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nature Biotechnology. 33(4). 415–423. 220 indexed citations

13.

Liu, Suhu, Sarah R. Walker, Erik A. Nelson, et al.. (2014). Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2. Molecular Cancer Therapeutics. 13(5). 1194–1205. 51 indexed citations

14.

Chapuy, Bjoern, Michael R. McKeown, Charles Y. Lin, et al.. (2014). Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma. Cancer Cell. 25(4). 545–546. 13 indexed citations

15.

Vogl, Dan T., Edward A. Stadtmauer, Daniel F. Heitjan, et al.. (2014). Combined autophagy and proteasome inhibition. Autophagy. 10(8). 1380–1390. 314 indexed citations

16.

Shimamura, Takeshi, Zhao Chen, Margaret Soucheray, et al.. (2013). Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 19(22). 6183–6192. 158 indexed citations

17.

Zoeten, Edwin F. de, Liqing Wang, Kyle V. Butler, et al.. (2011). Histone Deacetylase 6 and Heat Shock Protein 90 Control the Functions of Foxp3 ⁺ T-Regulatory Cells. Molecular and Cellular Biology. 31(10). 2066–2078. 217 indexed citations

18.

Schwartz, Brian E., Matthias D. Hofer, Madeleine E. Lemieux, et al.. (2011). Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming. Cancer Research. 71(7). 2686–2696. 156 indexed citations

19.

Mühlenberg, Thomas, Yixiang Zhang, Andrew J. Wagner, et al.. (2009). Inhibitors of Deacetylases Suppress Oncogenic KIT Signaling, Acetylate HSP90, and Induce Apoptosis in Gastrointestinal Stromal Tumors. Cancer Research. 69(17). 6941–6950. 74 indexed citations

20.

Bradner, James E.. (2009). A pulse at the heart of targeted therapy. Nature Chemical Biology. 5(3). 144–145. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact